Osteoporosis

Clinical trial of Dentonin initiated

Published in Women's Health Weekly, January 23rd, 2003

Acologix, Inc., initiated the phase I clinical study of its lead compound Dentonin (AC-100) to support its primary indication, osteoporosis.

Dentonin demonstrated significant bone formation activities in several models and a favorable safety profile in preclinical toxicology studies. The IND was filed in late October leading to the administration to the first human subjects in December. This first study will address safety and pharmacokinetics in healthy volunteers. A follow on study is expected to begin in 2003 where biological activity will be assessed by monitoring biochemical markers of bone metabolism. Publications regarding the biological activities of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2003-01-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry